Odense C

• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer Pending
  2025-523972-21-00 7 Extensive-Stage Small Cell Lung Cancer
• Prevention of chronic headache with anti-CGRP antibody treatment in patients with idiopathic intracranial hypertension Pending
  2025-524822-16-00 5 Idiopathic intracranial hypertension
• SCARFREE-001: Verteporfin for Scar Prevention Pending
  2025-525083-14-00 4 Scar formation following surgical wounds
• RESET C2 Pending
  2026-525214-62-00 4 Localised dMMR Colon Cancer
• Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid … Recruiting
  2025-521911-38-00 7 2026-05-26 Advanced HR+/HER- breast cancer
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study) Recruiting
  2025-522125-36-00 3 2026-04-22 Chronic hepatitis D infection
• Short title: A novel concept for local treatment of the elderly and fragile women with advanced ovarian cancer. Recruiting
  2025-522269-30-00 4 2026-04-07 Ovarian cancer
• A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bro … Recruiting
  2025-522892-27-00 4 2026-03-21 Bronchiectasis
• A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Recruiting
  2025-522553-19-00 10 2026-02-25 Symptomatic genetic and familial dilated cardiomyopathy.
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• A randomized controlled phase II, double blinded trial to investigate pulmonary function after treatment with rituximab compared to placebo … Recruiting
  2024-517667-23-00 4 2025-12-17 Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 4 2025-11-25 Mantle Cell Lymphoma (MCL)
• A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting
  2025-520623-24-00 7 2025-11-19 MTAP-deleted Solid Tumors
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight

Showing 25–48 of 457 trials